


PHARMACEUTICAL 2022

Nuvalent Inc. Rank 77 of 475







RealRate

PHARMACEUTICAL 2022

Nuvalent Inc. Rank 77 of 475

The relative strengths and weaknesses of Nuvalent Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Nuvalent Inc. compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 223% points. The greatest weakness of Nuvalent Inc. is the variable Revenues, reducing the Economic Capital Ratio by 35% points.

The company's Economic Capital Ratio, given in the ranking table, is 83%, being 359% points above the market average of -276%.

Input Variable	Value in 1000 USD
Assets, Current	290,628
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	8,787
Liabilities, Non-Current	0
Other Assets	3,196
Other Compr. Net Income	-228
Other Expenses	0
Other Liabilities	0
Other Net Income	-521
Property and Equipment	0
Research and Development	35,559
Revenues	0
Selling, General and Administrative Expense	10,258

Output Variable	Value in 1000 USD
Assets	293,824
Liabilities	8,787
Expenses	45,817
Stockholders Equity	285,037
Net Income	-46,338
Comprehensive Net Income	-46,452
Economic Capital Ratio	83%

